Previous 10 | Next 10 |
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.81. Approximately 109,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. share prices have moved between a 52-week high of $...
Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $5.61. This new high was reached on below average trading volume as 109,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. Catalyst Pharmaceuticals Inc. ...
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare dise...
Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q1 2021 Earnings Call May 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Catalyst Pharmaceuticals Inc (CPRX) Q1 2021 Earnings Call Tran...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Alicia Grande – Vice President, Chief Financial Officer and Treasurer Patrick McEnany – Chairman and Chief Executive Officer Jeffrey Del Carmen – Chief Comm...
-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in Japan -$143.3 Million in Cash and Investments and no Fun...
For under-the-radar companies, it's important to make sure any positive news finds its way to the eyes or ears of investors. The first quarter of 2021 is evidence of that for one small player dedicated to treating rare diseases in the pharmaceutical market. Catalyst Pharmaceuticals (N...
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare dis...
It has been one year since the markets bottomed in March of 2020 due to COVID. Markets have rebounded beyond most investors’ expectations, with growth and tech stealing much of the spotlight. The “rotation into value” narrative has recently gained some tractio...
Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...